Intuitive Surgical Inc.
) revealed that it expects revenues of $576 million for the
fourth quarter of 2013, reflecting a 5% decline from the year-ago
level of $609 million. As a result, ISRG shares fell 1.7% after
the market closed yesterday. However, expected revenues were
higher than the Zacks Consensus Estimate of $556 million.
For full-year 2013, Intuitive Surgical expects revenues of $2,265
million, up 4% from $2,179 million in the prior year and up 1%
from the Zacks Consensus Estimate of $2,245 million.
Expected Segment Results
Instruments and Accessories:
ISRG anticipates revenues in this segment to go up 6% to $268
million in the quarter from $254 million in the prior-year
quarter. For full-year 2013, Intuitive Surgical expects revenues
to rise 14% to $1,033 million. The revenue growth in both the
periods was attributable to rise in da Vinci procedure, partially
offset by a reduction in stocking orders related to a fall in
According to ISRG, about 523,000 surgical procedures were
performed with the help of da Vinci Surgical System in 2013, up
16% from 450,000 procedures performed in 2012. The growth was
attributable to rises in general surgery procedures in the U.S.,
gynecologic procedures in the U.S., and urology procedures
outside of the U.S. In the fourth quarter of 2013, da Vinci
procedures grew 12% from the prior-year quarter.
Intuitive Surgical expects da Vinci Surgical Systems revenues to
go down by 23% to roughly $205 million from $265 million in the
2012-quarter as 37 fewer da Vinci Surgical Systems were sold
compared with 175 systems in the fourth quarter of 2012. For the
full year 2013, Systems revenues expected to drop 11% to $835
million as 74 fewer units were sold compared with 620 systems in
Lower Systems revenues were attributable to moderating procedure
growth in benign gynecology, and changing hospital capital
spending priorities associated with the implementation of the
Affordable Care Act, partially offset by higher international
systems sales, due to better da Vinci system sales in Japan.
ISRG anticipates revenues from this segment to enhance 14% to
$103 million in the 2013-fourth quarter from $91 million in the
2012-quarter. For the full year, Intuitive Surgical expects
revenues to grow 16% to $397 million from $343 million in 2012.
Intuitive Surgical expects to release its detailed fourth quarter
and full year 2013 results on Jan 23, 2014. Currently, shares of
the company retain a Zacks Rank #4 (Sell).
Some better-ranked in the medical instruments industry include
Natus Medical Inc.
). CryoLife and Natus Medical carry a Zacks Rank #1 (Strong Buy),
while AngioDynamics carries a Zacks Rank #2 (Buy).
ANGIODYNAMICS (ANGO): Free Stock Analysis
NATUS MEDICAL (BABY): Free Stock Analysis
CRYOLIFE INC (CRY): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
To read this article on Zacks.com click here.